



Expert Review of Clinical Pharmacology >
Volume 5, 2012 - Issue 5

43 Views | 11 CrossRef citations to date | 1 Altmetric

Editorial


Medicines for pediatric oncology: can we overcome the failure to deliver?

Agnes Saint-Raymond & Ralf Herold

Pages 493-495 | Published online: 10 Jan 2014

🗨️ Cite this article 🔗 <https://doi.org/10.1586/ecp.12.51>

Sample our
Bioscience
Journals



>> **Sign in here** to start your access
to the latest two volumes for 14 days

📄 Full Article

🖼️ Figures & data

📖 References

🗨️ Citations

📊 Metrics

📄 Reprints & Permissions

Read this article

We Care About Your Privacy

We and our 843 partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Privacy Policy](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.

List of Partners (vendors)

I Accept

Essential Only

Show Purpose



For reprint orders, please contact reprints@expert-reviews.com

Medicines for pediatric oncology: can we overcome the failure to deliver?

Expert Rev. Clin. Pharmacol. 5(5), 493–495 (2012)



Agnes Saint-Raymond

Author for correspondence:
European Medicines Agency,
7 Westferry Circus, Canary
Wharf, London E14 4HB, UK
Tel: +44 207 523 7017
Fax: +44 207 523 7040
agnes.saint-raymond@ema.europa.eu



Ralf Herold

European Medicines Agency,
7 Westferry Circus, Canary
Wharf, London E14 4HB, UK

“The way forward regarding pediatric oncology is under discussion by the Committee and may include revoking the condition waivers, giving back to the Committee the possibility to analyze the mechanism of action and target of the new medicines in order to eventually obtain the necessary data in children within a reasonable timeframe.”

To date, children do not have access to the medicines necessary to treat pediatric cancers. Pediatric tumors have different names and specificities from adult tumors that go far beyond the naming issue. In most other therapeutic areas, with the main exception in pediatric rheumatology, the diseases affecting children are close to those affecting adults with respect to type of diseases and pathophysiology. Owing to specific gene mutation and expression profiles and fast tumor growth, cancers affecting children are different. An aggravating factor for the lack of authorized medicines is the rarity of the diseases, representing a small market overall, although they are frequent among serious pediatric diseases. Cancer represents the second main cause of death in children and treatments place a heavy burden on the child and his or her family. The uncertainties on long-term prognosis owing to potential late relapses, as well as complications of chemotherapy and radiotherapy add to this burden. However, pediatric oncology is also the area where treatments have achieved outstanding results through rigorous protocols (using medicines off-label), resulting in long-term survival and cures [1].

Another paradox is that most of the treatments used today were established by academics and hospital pediatric oncologists over the last decades, generally with little help or interest from large

pharmaceutical companies. This meant in practice that access to anticancer medicines was always significantly delayed for children [2] in contradiction with ethical principles and existing guidelines such as the International Conference on Harmonization guideline on the development of pediatric medicines (E11), which requires simultaneous submission for adults and children when the disease is serious or life threatening, when there are limited or no therapeutic alternatives [10].

In fact, behind the success lies another reality. If most of the success comes from effective treatments of acute pediatric leukemia and lymphoma, many other tumors – especially advanced stages and those of the CNS such as high-grade glioma – remain without effective therapeutic options, with short survival and devastating effects on the child and the family [3].

Regulatory initiatives in the USA, then in Europe, aim to ensure that medicines intended for adults are developed for children where there are unmet pediatric needs [10,10]. Unfortunately, to date in pediatric oncology these have not been so successful for several reasons. As part of the US Best Pharmaceutical for Children Act (BPCA), the US FDA can issue Written Requests based on public health needs describing how a company can develop a medicine for children, with the prospect of getting additional

EXPERT
REVIEWS

KEYWORDS: child • development • medicines • oncology • regulation



Disclaimer

The views expressed in this article are the views of the author and do not necessarily represent the views of the publisher or the editorial board.

Financial support

The author has no financial or other interests in any of the products or companies mentioned in this article.

be
fic

organization
ter or
ncies,

honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

> [Access through your institution](#)

Log in to Taylor & Francis Online

> [Log in](#)

Restore content access

> [Restore content access for purchases made as guest](#)

Purchase options *

[Save for later](#)

PDF download + Online access

- 48 hours access to article PDF & online version
- Article PDF can be downloaded
- Article

USD \$



[Add to cart](#)

Issue

- 30 da
- Ar
-

USD \$



[Add to cart](#)

* Local tax

Related Research

Recommended articles

Cited by
11

Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign up

Copyright

Access

Registered
5 Howick Pl

or & Francis Group
orma business

